Full Text View
Tabular View
No Study Results Posted
Related Studies
Effect of the HIV Protease Inhibitors Atazanavir and Lopinavir/Ritonavir on Cardiovascular Disease Risk Factors
This study has been completed.
Study NCT00720590   Information provided by National Heart, Lung, and Blood Institute (NHLBI)

First Received on July 21, 2008.   Last Updated on August 29, 2008   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Endothelial Dysfunction
Additional conditions recognized in this trial
Cardiovascular Diseases
Interventions listed in this trial
Atazanavir
Lopinavir/ritonavir
Placebo
Additional drug interventions recognized in this trial
HIV Protease Inhibitors
Lopinavir
Protease Inhibitors
Ritonavir
More general drug interventions related to this trial
Anti-HIV Agents
Anti-Infective Agents
Anti-Retroviral Agents
Antiviral Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Therapeutic Uses
Sponsors listed in this trial
National Heart, Lung, and Blood Institute (NHLBI)


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services